Tianjin Chase Sun Pharmaceutical Co.,Ltd

SZSE:300026 Stock Report

Market Cap: CN¥11.9b

Tianjin Chase Sun PharmaceuticalLtd Management

Management criteria checks 3/4

Tianjin Chase Sun PharmaceuticalLtd's CEO is Dan Zheng, appointed in Mar 2017, has a tenure of 7.67 years. directly owns 0.05% of the company’s shares, worth CN¥5.88M. The average tenure of the management team and the board of directors is 7.7 years and 5.2 years respectively.

Key information

Dan Zheng

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentagen/a
CEO tenure7.7yrs
CEO ownership0.05%
Management average tenure7.7yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

Nov 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Nov 01
We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Sep 26
Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Jun 12
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

May 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

May 21
This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04
Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

CEO

Dan Zheng (60 yo)

7.7yrs

Tenure

CN¥2,608,700

Compensation

Ms. Dan Zheng serves as General Manager of Tianjin Chase Sun Pharmaceutical Co.,Ltd since March 24, 2017 and serves as its Vice Chairman since April 24, 2019. She serves as Director of Tianjin Chase Sun Ph...


Leadership Team

NamePositionTenureCompensationOwnership
Dan Zheng
GM & Vice Chairman7.7yrsCN¥2.61m0.050%
CN¥ 5.9m
Wu Jun Lan
Executive GM12.9yrsCN¥1.81m0.050%
CN¥ 5.9m
Wu Sun
Deputy GMno dataCN¥979.30kno data
Chun Xu Li
Deputy GMno dataCN¥1.11m0.022%
CN¥ 2.7m
Rui Qiang Chen
GM of Human Resource Center & Deputy GMno dataCN¥1.21m0.023%
CN¥ 2.7m
Kun Zhang
Deputy General Manager7.7yrsCN¥1.32m0.031%
CN¥ 3.7m
Xiao Zhong Lu
Deputy General Manager2.6yrsCN¥1.76mno data

7.7yrs

Average Tenure

49yo

Average Age

Experienced Management: 300026's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dan Zheng
GM & Vice Chairman7.6yrsCN¥2.61m0.050%
CN¥ 5.9m
Wu Jun Lan
Executive GM5.6yrsCN¥1.81m0.050%
CN¥ 5.9m
Wu Sun
Deputy GM5.6yrsCN¥979.30kno data
Chun Xu Li
Deputy GMless than a yearCN¥1.11m0.022%
CN¥ 2.7m
Xiaoqing Yao
Chairman24.2yrsCN¥2.66m10.24%
CN¥ 1.2b
Peng Fei Tu
Independent Director4.8yrsCN¥120.00kno data
Dan Liang
Employee Representative Member of Supervisory Board & Securities Affairs Representative11.6yrsCN¥91.00kno data
Shengtian Wang
Independent Director6.9yrsCN¥120.00kno data
Tao Gong
Independent Director4.8yrsCN¥120.00kno data
Li Li
Independent Director4yrsCN¥120.00kno data
Sen Lin
Directorless than a yearno datano data
Juan Chen
Director1.3yrsno datano data

5.2yrs

Average Tenure

55yo

Average Age

Experienced Board: 300026's board of directors are considered experienced (5.2 years average tenure).